Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors

Br J Dermatol. 2018 Jun;178(6):1462-1463. doi: 10.1111/bjd.16479. Epub 2018 Apr 16.

Authors

H Horikawa¹, Y Kurihara¹, T Funakoshi¹, N Umegaki-Arao¹, H Takahashi¹, A Kubo¹, A Tanikawa¹, N Kodani^{2

3}, Y Minami², S Meguro², H Itoh², K Izumi⁴, W Nishie⁴, H Shimizu⁴, M Amagai¹, J Yamagami¹

Affiliations

¹ Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
² Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
³ Center for Preventative Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
⁴ Department of Dermatology, Hokkaido University Graduate School of Medicine, Kita-ku, Sapporo, Japan.

PMID: 29478242
DOI: 10.1111/bjd.16479

No abstract available

Publication types

Letter

MeSH terms

Aged
Dipeptidyl-Peptidase IV Inhibitors / adverse effects*
Drug Eruptions / etiology*
Female
Humans
Hypoglycemic Agents / adverse effects*
Male
Pemphigoid, Bullous / chemically induced*
Phenotype
Retrospective Studies

Substances

Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents